Table 3 Compliance with the guidelines in 2016 and 2018 for cases with aURTD^a, FLUTD^b and abscesses

AMU^cindicated

n = 64

n = 78

n = 57

n = 55

n = 65

n = 82

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

Guidelines followed

10.9 [4.5–21.2]

16.7 [9.2–26.8]

38.6 [26.0–52.4]

45.5 [32.0–59.4]

50.8 [38.1–63.4]

41.5 [30.7–52.9]

a. Different dose/duration

6.3 [1.7–15.2]

2.6 [0.3–9.0]

1.8 [0.0–9.4]

5.5 [1.1–15.1]

24.6 [14.8–36.9]

34.1 [24.0–45.4]

b. Different antimicrobial class

75.0 [62.6–85.0]

67.9 [56.4–78.1]

54.4 [40.7–67.6]

38.2 [25.4–52.3]

21.5 [12.3–33.5]

22.0 [13.6–32.5]

c. Unjustified non-use

7.8 [2.6–17.3]

12.8 [6.3–22.3]

5.3 [1.1–14.6]

10.9 [4.1–22.2]

3.1 [0.4–10.7]

2.4 [0.3–8.5]

AMU^cnot indicated

n = 120

n = 92

n = 106

n = 109

n = 66

n = 47

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

Guidelines followed

35.0 [26.5–44.2]

55.4 [44.7–65.8]

55.7 [45.7–65.3]

67.9 [58.3–76.5]

4.5 [0.9–12.7]

19.1 [9.1–33.3]

Treatment duration^e

n = 140

n = 127

n = 178

n = 134

n = 153

n = 164

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

% [CI]^d

Guidelines followed

89.3 [82.9–93.9]

88.2 [81.3–93.2]

44.4 [37.0–52.0]

54.5 [45.7–63.1]

39.2 [31.4–47.4]

39.6 [32.1–47.6]

a. Too long

10.7 [6.1–17.1]

10.2 [5.6–16.9]

50.6 [43.0–58.1]

38.8 [30.5–47.6]

57.5 [49.3–65.5]

56.1 [48.1–63.8]

b. Too short

0.0 [0.0–2.6]

1.6 [0.2–5.6]

5.1 [2.3–9.4]

6.7 [3.1–12.4]

3.3 [1.1–7.5]

4.3 [1.7–8.6]